Capsida has stated that it still does not know what led to the death associated with its gene therapy treatment. This uncertainty raises questions within the scientific community.
Many experts in the gene therapy field are expressing frustration over the time lost while Capsida remained silent about the specific brain receptor targeted during the treatment.
The incident highlights the ongoing challenges and risks associated with gene therapy, emphasizing the need for transparency and communication in the field.